Nuformix plc Appoints Anne Brindley as Executive Director
December 07, 2020 at 12:30 pm IST
Share
Nuformix plc announced the appointment of Dr. Anne Brindley as Executive Director of the Company with immediate effect. Anne has over 30 years' experience in Big Pharma, Biotech and smaller R&D companies, with a proven international track record of leading organizations through strategic change and driving projects and portfolios through discovery and development to market. Before moving to Advent, Anne was a Board member and Managing Director of Respivert Ltd, a subsidiary of Janssen Pharmaceuticals (part of Johnson & Johnson, Inc), where she was responsible for leadership and operations of the company, including discovery /development programmes spanning three novel classes of drug for idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and asthma, as well as out-licensing activities. Prior to this, Anne occupied the role of Vice President and Head of Inhalation Products.
Share
© S&P Capital IQ - 2020